Synergy CHC Corp (SNYR): Price-to-Revenue Coefficient

Symbol and logo of brand Synergy CHC Corp (SNYR)

Geopolitical instability is disrupting raw material logistics and reducing American purchasing power, which pressures the profitability of Synergy CHC Corp (SNYR). The estimated P/S on GURU.Markets contains a breaking point caused by severe pressure in the online segment and stagnation in the consumer cycle. However, the efficiency of D2C channels and IT infrastructure mitigate these risks. The value of 0.00 indicates the level of this metric.

SNYR Synergy CHC Corporation Price-to-Revenue Ratio (04/02/2025 - 10/03/2026)

Metric breakdowns and analytics for Synergy CHC Corp. (SNYR)

- share price and consensus valuation forecast:
General company analysis:Synergy CHC Corp
Mass-produced product of Synergy CHC

The outsourcing model of Synergy CHC Corp (SNYR) shifts production risks to external contractors, making revenue a key indicator of management efficiency. The fundamental P/S ratio reflects the market value of the business relative to its annual turnover, allowing for an assessment of the cost per unit of sales. This metric is calculated as the ratio of market capitalization to the company's total revenue. Extremely low values on this chart may signal a "value trap" and the risk of long-term capital stagnation.

Who Synergy CHC Corp competes with

HLN (Haleon) - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Kenvue Inc KVUE|Verona Pharma Corp - Price-to-Revenue Ratio|MENS: Market Cap to Revenue|Price-to-Revenue Coefficient Ligand Pharmaceuticals LGND|Amneal Pharmaceuticals Inc (AMRX) - Price-to-Revenue Ratio|Perrigo Company PLC - Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio alvotech.com|P/S Multiple Liquidia Technologies|Price-to-Revenue Ratio Galapagos Genomics (GLPG)|ANIP: Price-to-Sales Ratio|P/S Multiple MNKD (MannKind Corp)|Price-to-Revenue Coefficient Amphastar (AMPH)|PCRX: Market Cap to Revenue|SPRY - P/S Multiple|Theravance Biopharma, Inc. (TBPH) - Price-to-Revenue Ratio|AQST (Aquestive Therapeutics) - Price-to-Revenue Ratio|SCPH (scpharmaceuticals.com) - P/S Multiple|TECX: Market Capitalization-to-Revenue Ratio|Price-to-Revenue Ratio Tonix Pharmaceuticals Inc. (TNXP)|SXTC (SXT Pharmaceuticals) - Market Capitalization-to-Revenue Ratio|P/S Multiple EPRX (Eupraxia Pharmaceuticals)|Market Capitalization-to-Revenue Ratio BHST|Invizyne Technologies - P/S Multiple|oramed.com (ORMP) - Market Cap to Revenue|ENTX (enterabio.com) - Market Cap to Revenue|Market Cap to Revenue Ratio HYFT|ABVC (ABVC BioPharma, Inc) - P/S Multiple|P/S Multiple cumberlandpharma.com|Price-to-Revenue Ratio Quantum BioPharma (QNTM)|FibroGen (FGEN) - Price-to-Revenue Multiple|P/S Multiple TELO (telomirpharma.com)|RANI - Market Cap to Revenue|RLYB: Market Cap to Revenue|lexariabioscience.com (LEXX) - Market Cap to Revenue|Pulmatrix Inc (PULM) - Price-to-Revenue Ratio|PTHL: Market Cap to Sales Volume|APM (Aptorum Group Ltd) - P/S Multiple|Lyra Therapeutics Inc (LYRA) - Price-to-Revenue Coefficient|P/S Multiple IBO|Market Cap to Sales Volume TNFA|cbdMD, Inc. - Market Cap to Revenue|Market Capitalization-to-Revenue Ratio PRFX|Altamira Therapeutics Ltd. - P/S Multiple|LIPO: Price-to-Revenue Ratio|OPTN: P/S Multiple|Price-to-Sales Ratio PIRS (Pieris Pharmaceuticals)|PROC (Procaps) - P/S Multiple|PTPI (Petros Pharmaceuticals Inc) - Market Cap to Sales Volume|P/S Multiple QLI|SLRN - Price to Sales|P/S Multiple TFFP (TFF Pharmaceuticals, Inc)